![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Approves Roche’s PD-L1 Biomarker Assay
FDA Approves Roche’s PD-L1 Biomarker Assay
![roche.gif](https://www.fdanews.com/ext/resources/test/Device_Images/roche.gif?t=1600727553&width=430)
The FDA has approved Roche’s Ventana PD-L1 assay, a complementary diagnostic tool for assessing PD-L1 status in patients suffering from metastatic urothelial cancer who are considering treatment with Roche’s Tecentriq.
The assay determines PD-L1 status through immune cell staining to help aid immunotherapy decisions.
The in vitro test uses immunohistochemistry technology to “visually enhance and score [the] PD-L1 protein on tumor-infiltrating immune cells,” according to the company. — Anisa Jibrell
Upcoming Events
-
11Jul
-
18Jul
-
21Oct